Cascadian Therapeutics Inc (CASC) Receives $6.00 Consensus PT from Analysts

Shares of Cascadian Therapeutics Inc (NASDAQ:CASC) have been given a consensus rating of “Hold” by the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $6.00.

CASC has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Raymond James Financial downgraded shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Finally, ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 31st.

Hedge funds have recently bought and sold shares of the stock. New York State Common Retirement Fund acquired a new stake in Cascadian Therapeutics in the second quarter worth about $136,000. Rhumbline Advisers acquired a new stake in Cascadian Therapeutics in the 2nd quarter valued at about $143,000. SG Americas Securities LLC lifted its holdings in Cascadian Therapeutics by 194.7% in the 4th quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 25,464 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Cascadian Therapeutics in the 4th quarter valued at about $181,000. Finally, Alps Advisors Inc. acquired a new stake in Cascadian Therapeutics in the 4th quarter valued at about $207,000. 80.59% of the stock is owned by institutional investors and hedge funds.

Cascadian Therapeutics (CASC) traded down $0.01 during mid-day trading on Friday, reaching $9.99. 629,723 shares of the company traded hands, compared to its average volume of 1,364,232. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.21.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/02/15/cascadian-therapeutics-inc-casc-receives-6-00-consensus-pt-from-analysts.html.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply